Health Yuan Pharmaceutical Group Independent Director Hu Jing 2025 Annual Performance Report Released

In Data Health Yuant Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Health Yuant”) recently disclosed the 2025 annual work report of independent director Ms. Huo Jing. The report shows that during her tenure in 2025 (she stepped down in May 2025), Ms. Huo Jing strictly fulfilled the duties of an independent director and actively participated in corporate governance.

In terms of performing duties overview, Ms. Huo Jing attended two board meetings and one shareholders’ meeting in 2025, and cast a “yes” vote on all proposals. As the Chair of the Board Compensation and Evaluation Committee and a member of the Nomination Committee and the Strategy and Risk Management Committee, she chaired and participated in relevant specialized committee meetings, deliberating multiple important proposals, including the evaluation of compensation for senior executives, the nomination of independent director candidates, and the capital increase and share expansion of Zhizhu Bio for the Company’s holding subsidiary. In addition, she also attended 3 independent director specialized meetings, conducted in-depth discussions on matters such as related-party transactions and related-party guarantees, and formed her opinions.

The report focused on several corporate governance matters. Ms. Huo Jing reviewed related-party transactions and related-party guarantees during the reporting period and believed that the relevant decision-making procedures were lawful and compliant, and no circumstances were found that would harm the interests of the Company and its small and medium-sized shareholders. Regarding the Company’s financial and accounting report and the internal control evaluation report, she confirmed that they were true, accurate, and complete. For matters related to senior executives’ compensation and equity incentives, she focused on the process of canceling stock options due to performance evaluation not meeting requirements, and believed that the operation complies with relevant regulations.

In the report, Ms. Huo Jing assessed the performance of other independent directors and expressed her approval of the management team’s standardized operation of the Company. Although she has resigned, she still expressed her concern for and best wishes regarding the Company’s future development. This annual work report comprehensively demonstrates the positive role played by independent directors in overseeing the Company’s compliant operations and safeguarding the interests of small and medium-sized shareholders.

Endless information and precise interpretation—available on the Sina Finance app